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Airway Obstruction and Bronchodilator 
Responsiveness in Adults With Acute Cough
ABSTRACT
PURPOSE We sought to determine the prevalence of airway obstruction and bron-
chodilator responsiveness in adults consulting for acute cough in primary care.
METHODS Family physicians recruited 3,105 adult patients with acute cough (28 
days or shorter) attending primary care practices in 12 European countries. After 
exclusion of patients with preexisting physician-diagnosed asthma or chronic 
obstructive pulmonary disease (COPD), we undertook complete case analysis 
of spirometry results (n = 1,947) 28 to 35 days after inclusion. Bronchodilator 
responsiveness was diagnosed if there were recurrent complaints of wheezing, 
cough, or dyspnea and an increase of the forced expiratory volume in 1 second 
(FEV1) of 12% or more after bronchodilation. Airway obstruction was diagnosed 
according to 2 thresholds for the (postbronchodilator) ratio of FEV1 to forced vital 
capacity (FEV1:FVC): less than 0.7 and less than the lower limit of normal.
RESULTS There were 240 participants who showed bronchodilator responsiveness 
(12%), 193 (10%) had a FEV1/FVC ratio of less than 0.7, and 126 (6%) had a ratio 
of less than the lower limit of normal. Spearman’s correlation between the 2 
defi nitions of obstruction was 0.71 (P <.001), with discordance most pronounced 
among those younger than 30 years and in older participants.
CONCLUSIONS Both bronchodilator responsiveness and persistent airway obstruc-
tion are common in adults without established asthma or COPD who consult for 
acute cough in primary care, which suggests a high risk of undiagnosed asthma 
and COPD. Different accepted methods to defi ne airway obstruction detected dif-
ferent numbers of patients, especially at the extremes of age. As both conditions 
benefi t from appropriate and timely interventions, clinicians should be aware and 
responsive to potential underdiagnosis.
Ann Fam Med 2012;10:523-529. doi:10.1370/afm.1416. 
INTRODUCTION
Undetected chronic obstructive lung disorders in primary care, such as asthma and chronic obstructive pulmonary disease (COPD), are common in high-risk patients (eg, smokers) who 
complain of acute cough.1,2 Cough is among the most common conditions 
for which people seek health care,3 and family physicians could help their 
patients by considering underlying asthma or COPD when their patients 
consult them for acute cough. Timely treatment improves quality of life 
and reduces future exacerbations of these underlying conditions.4,5
Our searches identiﬁ ed only 2 relevant studies describing the proportion 
of underlying obstructive lung disorders in patients consulting their family 
physician for cough. Thiadens and colleagues6 included 192 patients (mean 
age of 44 years) consulting their family physician for cough persisting for 
at least 14 days; 74 were given a diagnosis of asthma (39%), and 14 were 
given a diagnosis of COPD (7%). Broekhuizen and colleagues7 included 353 
patients (mean age of 63 years) with cough lasting more than 14 days, 23 of 
whom were given a diagnosis of asthma (7%) and 102 were given a diagnosis 
of COPD (29%). Both studies were relatively small and the mean duration of 
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cough in the latter study was long (93 days). More fre-
quent visits and persistent cough are known to be asso-
ciated with diagnosis of COPD,8 whereas the relation 
with underlying obstructive airways disease and acute 
cough (≤28 days) has not previously been quantiﬁ ed.
We therefore set out to determine the prevalence 
of abnormal lung function results that could identify 
patients at high risk for a diagnosis of COPD or asthma 
in a large multicenter study of adult patients consulting 
their primary care physicians with acute cough.
METHODS
Ours was a cross-sectional prevalence study. Data were 
collected in 16 primary care research networks in 12 
European countries participating in the Genomics to 
Combat Resistance Against Antibiotics in Community-
acquired LRTI in Europe (GRACE) (http://www.grace-
lrti.org) Network of Excellence. Participating family 
physicians recruited consecutive patients who were aged 
18 years or older, with acute cough as the main symp-
tom, and consulting for the ﬁ rst time for this disease epi-
sode. Although acute cough is usually deﬁ ned as fewer 
than 21 days, some studies have shown that cough can 
last more than 3 weeks.9 We therefore decided to adopt 
the broader inclusion criterion of 28 days or less for 
acute cough. Nonwhite patients were excluded because 
of ethnic differences in lung function reference values.10 
Other exclusion criteria for this analysis were diagnosis 
of asthma or COPD in the clinical record at the time 
of the index consultation and serious causes of compro-
mised immunity. All patients provided written informed 
consent, and the study was approved by the medical 
ethics committees of all participating centers.
Measurements
Family physicians recorded the participants’ history 
(eg, current complaints, comorbidity, medications) and 
ﬁ ndings from the physical examination on a standard-
ized case report form. Spirometry was performed 
according to a strict protocol between day 28 and 35 
after inclusion with the aim of obtaining results during 
a stable phase.4,11 Staff in the participating primary care 
centers underwent standardized training in spirometry. 
Measurements included the forced vital capacity (FVC) 
and the forced expiratory volume in 1 second (FEV1) 
before and at least 15 minutes after bronchodilation 
with 400 mg of salbutamol. The best of a minimum of 
3 acceptable retained ﬂ ow volume curves was used to 
determine the postbronchodilator FEV1:FVC ratio.4
Diagnostic Outcome
Bronchodilator responsiveness was diagnosed if recur-
rent (more than 1 other episode in the past year) 
wheezing, cough, or chest tightness were present 
(patient reported) in combination with an increase 
in FEV1 of at least 12% or more than 200 mL after 
bronchodilation. Persistent airway obstruction was 
diagnosed on the basis of the postbronchodilator 
FEV1:FVC ratio. According to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), a ratio of 
less than 0.7 conﬁ rms COPD.4 Because the FEV1:FVC 
ratio physiologically decreases with age, however, there 
is controversy about using a ﬁ xed threshold to deﬁ ne 
obstruction4,12; others base a deﬁ nition of obstruction 
on the lower limit of normal (LLN) of the FEV1:FVC 
ratio according to sex and age.13 The presence of airway 
obstruction in our study was deﬁ ned by both methods: 
(1) a ﬁ xed FEV1:FVC ratio of less than 0.7 according to 
GOLD (obstruction GOLD), and (2) FEV1:FVC ratio 
of less than the LLN according to the European Respi-
ratory Society guidelines (obstruction LLN).14 Cor-
relation between the 2 deﬁ nitions was calculated with 
Spearman’s rank correlation coefﬁ cient.15
Data Analysis
Only participants with complete spirometry results 
were included in the present analysis. For the included 
participants, missing results (apart form spirometry) 
were imputed using multiple regression techniques. 
Data were analyzed using SPSS 17.0 for Windows 
(SPSS Inc) and R 2.8.1 (R Project for Statistical Com-
puting).16 The prevalence of asthma, COPD GOLD, 
and COPD LLN was calculated for the entire study 
population and for subgroups of age, sex, and smoking 
history (current, past, never). These groups were com-
pared using χ2 tests.
RESULTS
Patient Characteristics
Family physicians recruited 3,105 participants with 
acute cough. Participants with preexisting physician-
diagnosed (according to the physicians’ medical ﬁ le) 
asthma (n = 329), physician-diagnosed COPD (n = 183), 
those who were of nonwhite ethnicity (n = 87), and 
those who had incomplete spirometry results (n = 585) 
were excluded, resulting in 1,947 participants for the 
analysis (Figure 1).10 Less than 0.1% of history items, 
1% of physical examination items, and 12% of diary 
data were missing (Table 1). In some countries, spirom-
etry measurements were available for only a minority 
of participants (eg, Italy and Slovakia, Supplemental 
Appendixes 1 and 2, available at http://annfa-
mmed.org/content/10/6/523/suppl/DC1). There 
were no important differences between study par-
ticipants with and without spirometry results, apart 
from mean age (46 years for those without spirometry, 
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data not shown). The mean age of the study popula-
tion was 50 years (SD = 16 years), 40% (n = 770) were 
male, mean height was 168 ± 9 cm, and mean weight 
was 76 ± 16 kg. Mean duration of cough before consul-
tation (9 days) and average day of recovery (12 days) 
were similar in participants with and without unde-
tected asthma or COPD.
Prevalence of Obstruction and Reversibility
Of the 1,947 participants, 240 met our diagnostic 
criteria for bronchodilator responsiveness (12%), of 
whom 193 showed a FEV1 increase of both 200 mL 
and 12%; 193 (10%) had airway obstruction GOLD 
and 126 (6%) had airway obstruction LLN (Spearman’s 
ρ = 0.71, P <.001). Of the participants with obstruction 
GOLD and LLN, 92 and 67, respectively, reported 
recurrent respiratory symptoms (more than 2 cough 
episodes or had awakened with more than once with 
chest tightness last year).
In total, 202 (10%) participants met obstruction cri-
teria according to at least 1 of the 2 deﬁ nitions, and 41 
participants showed both bronchodilator responsive-
ness and obstruction (2%) (Table 1). Of the 193 par-
ticipants with obstruction GOLD, 86 cases (45%) had 
an FEV1 above the 80% predicted according to age, 
sex, and height; 84 (44%) had an FEV1 between the 
50% and 80% predicted; 17 (8%) had an FEV1 between 
the 30% and 50% predicted, and 6 (3%) had an FEV1 
of less than the 30% predicted.
The prevalence of bronchodilator responsive-
ness and airway obstruction (GOLD or LLN) varied 
largely per country and was related to the proportion 
of known asthma and COPD (Supplemental Appendix 
2, available at http://annfammed.org/content/10/6/523/
suppl/DC1).
The prevalence of bronchodilator responsiveness 
was 15% in participants younger than 50 years and 
11% in participants aged 50 years and older (P = .004), 
14% in male and 12% in female participants (P = .18), 
11% in never or past smokers, and 16% in current 
smokers (P = .02). In participants with duration of 
cough shorter than 14 days at the ﬁ rst consultation, the 
prevalence of reversibility was 12% and 14% if dura-
tion was 14 days or longer (P = .20, Table 2).
The prevalence of obstruction (GOLD or LLN) 
was 6% in participants younger than 50 years and 14% 
in participants aged 50 years and older (P <.001), 11% 
in male and 10% in female participants (P = .75), 9% 
in never smokers and 10% in past and 13% in current 
smokers (P = .10). In participants with cough for fewer 
than 14 days at the ﬁ rst consultation, obstruction was 
found 10%; in those with complaints longer than 14 
days, it was 11% (P = .82, Table 2).
More participants showed obstruction GOLD than 
LLN, apart from in the under-30-year age-group, with 
the discordance highest in participants aged older than 
50 years (14% vs 7% for airway obstruction GOLD 
and LLN, respectively (Figure 2).
DISCUSSION
Main Findings
In adult patients without preexisting physician diag-
nosed asthma or COPD who consulted for acute 
cough in primary care and who underwent pre- and 
postbronchodilator spirometry 4 weeks later, 13% 
showed bronchodilator responsiveness, together with 
a history of recurrent airway symptoms. People with 
repeated episodes of acute cough and reversible airway 
obstruction may have undiagnosed asthma. Obstruc-
tive spirometry according to the GOLD deﬁ nition was 
present in 10% and according to the LLN deﬁ nition 
in 6% of the patients. The GOLD deﬁ nition classiﬁ ed 
more participants with an obstructive condition than 
did the LLN deﬁ nition, especially among older partici-
pants. Although these ﬁ ndings are necessary but not 
sufﬁ cient to diagnose COPD and asthma, patients with 
these ﬁ ndings are at higher risk of having (yet unde-
tected) chronic obstructive lung disease and might 
beneﬁ t from ongoing treatment.
Figure 1. Flowchart of the study and participants.
3,105 Patients with acute 
cough included
2,619 Patients without 
known lung disorder
2,352 Patients with white 
ethnicity
1,947 Patients with all 
measurements available
486 Patients excluded
 329 with known asthma
 183 with known COPD
87 Patients from other eth-
nic groups excluded
585 Patients with missing or 
incomplete spirometry data 
excluded
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Strengths and Limitations
We studied a clinically relevant population, namely, 
those consulting their family physician for respira-
tory complaints (acute cough), whereas most previ-
ous studies included only asymptomatic volunteers 
(open-population studies).17-19 Moreover, we studied the 
prevalence of lung function abnormalities in 12 Euro-
pean countries, whereas most other studies were from 
a single country. Reviews mention considerable varia-
tion in reported prevalence of obstructive lung disease, 
attributed to differences in risk exposure, population 
characteristics, methods, and deﬁ nitions used to mea-
sure disease.18,20 In our pan-European study, standard-
ized measurements were used, and population differ-
ences were taken into account in analyses, increasing 
generalizability of the results. Finally, we measured 
spirometry results 4 weeks after an index consultation, 
when most acute episodes of cough had resolved.
A limitation of our study is that a formal clinical 
diagnosis of asthma and COPD could not be estab-
lished within our research design. We were merely 
able to identify those with high risk of these disorders. 
Persistent airway obstruction is a hallmark of COPD 
(but can also develop in asthma, especially in smokers), 
and bronchodilator responsiveness suggests asthma 
and is common in COPD. There is no single reference 
standard to diagnose asthma and COPD; these diag-
noses should be based on clinical history and physical 
examination combined with spirometry results. Repeat 
spirometry and additional tests, such as body plethys-
mography for COPD and histamine- or methacholine-
provocation tests for asthma, can increase diagnostic 
certainty. We therefore considered that the diagnostic 
categories we used (bronchodilator responsiveness and 
airway obstruction) were most appropriate for report-
ing our results. Diagnostic certainty in our identiﬁ ed 
study participants could also have been be increased 
by speciﬁ c questionnaires for asthma and COPD; 
however, the diagnostic value of such questionnaires 
is uncertain. Our ﬁ ndings reinforce the need for more 
objective criteria to deﬁ ne asthma or COPD.
The differences in prevalence of airway obstruc-
tion and bronchodilator responsiveness that we found 
between countries might represent real differences, 
possibly caused by variation in air pollution or demo-
graphic characteristics. Moreover, the differences 
could also partly be explained by varying deﬁ nitions 
and guidelines between countries, because an active 
detection policy for asthma and COPD reduces the 
number of undetected cases (Supplemental Appendix 
2). A further limitation of our study is that differential 
patient selection (selection bias) between countries 
cannot be excluded, as we were not able to gather data 
on the eligible participants who were not included 
in the study. Another problem is the high number of 
Table 1. Characteristics of Adults Consulting for Acute Cough in Primary Care (N = 1,947) 
by Presence of Bronchodilator Responsiveness
Characteristic
Acute
Cough Responsiveness
Airway Obstruction
GOLDa LLNb 
History (day 1), No. (%) 1,947 (100) 240 (12) 193 (10) 126 (7%)
Age, mean (SD), y 50 (16) 47 (17) 58 (16) 50 (17)
Male, No. (%) 770 (40) 103 (43) 82 (43) 43 (34)
Current smoking, No. (%) 496 (26) 78 (33) 61 (32) 48 (38)
Pack-years of smoking, mean (SD), y 8 (14) 9 (17) 13 (20) 14 (21)
History of cardiovascular disease, No. (%) 171 (9) 17 (7) 22 (11) 8 (6)
Use of inhaled lung medication, No. (%) 50 (3) 14 (6) 6 (3) 3 (2)
Asthma in parents or siblings, No. (%) 423 (22) 68 (28) 37 (21) 25 (22)
Atopy or allergic disease, No. (%)d 732 (38) 116 (48) 71 (40) 52 (46)
Cough before consultation, mean (SD), d 9 (7) 9 (7) 9 (7) 8 (7)
Cough episodes last year, mean (SD), No. 2 (2) 3 (2) 2 (2) 2 (2)
Spirometry (day 28)
FEV1, mean (SD), L 3.0 (0.9) 3.2 (1.1) 2.1 (0.7) 2.0 (0.8)
FVC, mean (SD), L 3.7 (1.1) 4.0 (1.3) 3.5 (1.1) 3.6 (1.1)
FEV1:FVC ratio, mean (SD) 0.81 (0.11) 0.79 (0.12) 0.60 (0.11) 0.57 (0.12)
ERS = European Respiratory Society; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GOLD = Global Initiative for Chronic Obstructive Lung 
Disease; LLN = lower limit of normal.
a According to the GOLD defi nition: FEV1:FVC less than 0.70.4
b According to ERS: LLN of FEV1:FVC ratio for males: –0.18 × age + 87.21 – (1.64 × 7.17), for females: –0.19 × age + 89.10 – (1.64 × 6.51).14
c These 41 participants are also included in the categories bronchodilator responsiveness and airway obstruction.
d Atopic symptoms or allergic disease = hay fever, eczema, urticaria, or history of allergic reaction.
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missing or incomplete spirometry results for some 
countries (eg, Italy, Supplemental Appendixes 1 
and 2), resulting in unreliable 
prevalence estimates in those 
countries. We did not record 
whether missing spirometry 
data (19%) arose from uninter-
pretable results or whether spi-
rometry was not performed in 
these patients. Moreover, there 
was no additional standardized 
reassessment of all spirometry 
curves in our study, and the 
individual judgment of qual-
ity by the individual research 
staff members may have led to 
misclassiﬁ cation.
Participants were assessed 
using the equipment already 
available in the participating 
practices and so were assessed 
using a range of models and 
makes of spirometer (list avail-
able on request). Spirometry was 
performed according to a uni-
form protocol at all study sites, 
however, and all general practice 
staff members performing spi-
rometry were trained to analyze spirometry curves. A 
primary care study has shown that spirometry tests in a 
primary care setting conducted by staff with adequate 
training are comparable in quality to pulmonary func-
tion laboratory measurements.21 Finally, participants 
were included who were using inhaled lung medication, 
which may have inﬂ uenced their spirometry results. 
Even so, it is common for primary care patients to be 
treated with inhaled medication without ﬁ rst undergo-
ing diagnostic work-up for asthma or COPD.
Comparison With Other Studies
The prevalence of abnormal spirometry patterns in our 
study was lower than in other studies. The diagnostic 
outcomes we used, however, differed from those used 
in these previous studies. Thiadens and colleagues6 
found asthma in 39% and COPD in 7% of the cases, 
and Broekhuizen and colleagues7 found previously 
undetected COPD in 30%. Apart from the older age 
of participants in Broekhuizen’s study, the most likely 
explanation is that the average duration of cough was 
shorter in our study (8.7 days, with a self-reported 
recovery rate of 70% at 14 days). In an open-popu-
lation study of the presence of chronic lung diseases 
in 169 smokers, 18% had COPD, increasing to 27% 
among those with chronic cough.1
There was no notable variation in prevalence of 
airway obstruction among nonsmokers (9%), past 
Responsiveness 
and Obstruction
(GOLD or LLN)
No Responsiveness 
or Obstruction Missing
41 (2%)c 1,546 (79) 0 (0)
58 (16) 50 (16) 0 (0)
18 (44) 603 (39) 0 (0)
12 (29) 366 (24) 1 (0)
18 (27) 7 (13) 28 (1)
3 (7) 135 (9) 1 (0.1)
3 (7) 33 (2) 1 (0.1)
8 (20) 322 (21) 187 (10)
6 (39) 552 (36) 186 (10)
10 (7) 9 (7) 32 (2)
2 (2) 1 (2) 232 (12)
2.1 (0.6) 3.0 (0.9) 0 (0)
3.4 (1.0) 3.7 (1.0) 0 (0)
0.61 (0.08) 0.83 (0.08) 0 (0)
Table 2. Cough Duration of Adult Patients Consulting for Acute 
Cough in Primary Care (N = 1,947) by Presence of Bronchodilator 
Responsiveness and Obstruction
Duration of Cough
Bronchodilator 
Responsiveness
No. (%)a
Obstruction 
(GOLD or LLN)
No. (%)a
No Responsiveness 
or Obstruction
No. (%)
Total patients 240 (12) 202 (10) 1,546 (79)
Cough before consultation
<1 week 114 (12) 94 (10) 743 (80)
1-2 weeks 54 (11) 53 (11) 397 (80)
2-3 weeks 47 (15) 38 (12) 241 (77)
>3 weeks 25 (12) 17 (8) 165 (81)
Duration until recovery
<1 week 25 (11) 21 (9) 180 (80)
1-2 weeks 137 (13) 114 (11) 854 (79)
2-3 weeks 57 (12) 48 (11) 361 (79)
>3 weeks 21 (11) 19 (10) 151 (80)
Total cough duration
<1 week 2 (10) 1 (5) 17 (85)
1-2 weeks 46 (11) 41 (10) 346 (81)
2-3 weeks 88 (14) 71 (11) 510 (79)
>3 weeks 104 (12) 89 (11) 673 (79)
GOLD = Global Initiative for Chronic Obstructive Lung Disease; LLN = lower limit of normal.
a Including participants with both bronchodilator responsiveness and obstruction (n = 41).
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smokers (10%), and current smokers (13%) in our study, 
which is possibly related to the large number of miss-
ing results on smoking status. Alternatively, smokers 
may have been more likely to have had COPD previ-
ously diagnosed.
Studies in the general population found prevalence 
of obstructive lung disease that varied from 23% to 
29%, depending on diagnostic criteria.17-19 Likewise, 
ﬁ ndings from our study show that differences in age, 
sex, smoking status, and geographical population, as 
well as the deﬁ nition that is used, can result in sys-
tematic differences in international prevalence rates. 
The increasing airway obstruction GOLD prevalence 
with older age, ie, when using the ﬁ xed ratio, is in 
line with recent warnings for overdiagnosis of airway 
obstruction in older adults. Also, the higher prevalence 
according to the LLN deﬁ nition in younger partici-
pants is consistent with previous studies.13
Clinical Implications and Conclusions
An important proportion (approximately one-ﬁ fth) 
of adult patients without an established diagnosis of 
asthma or COPD consulting their family physician 
with acute cough showed subsequent airway obstruc-
tion or bronchodilator responsiveness, which suggests 
undetected asthma or COPD. Given effective pharma-
cological and lifestyle modiﬁ cation interventions, espe-
cially interventions to assist in quitting smoking, iden-
tifying and providing appropriate treatment and advice 
to these patients is likely to improve their quality of 
life and reduce exacerbations. Moreover, an accurate 
diagnosis could help to motivate smokers to quit.22 
Finally, detection of asthma and COPD may help to 
reduce unnecessary use of antibiotics in patients with 
acute cough, because a noninfectious cause (obstruc-
tion) will also be considered.
Different methods to deﬁ ne airway obstruction 
resulted in twofold differences in the prevalence esti-
mates among participants aged 50 years or more. Our 
results from symptomatic patients seeking health care 
uniquely conﬁ rm ﬁ ndings from open-population stud-
ies that a ﬁ xed cutoff value of 0.70 (GOLD) should 
be used to deﬁ ne obstruction with caution in the 
extremes of age.12,13
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/content/10/6/523.
Key words: acute cough; asthma; chronic obstructive pulmonary dis-
ease; primary health care; spirometry
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Figure 2. Prevalence of airway obstruction and bronchodilator responsiveness in patients consulting for 
acute cough, by diagnostic defi nition and age-group. 
ERS = European Respiratory Society; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GOLD = Global Initiative for Chronic Obstructive Lung 
Disease; LLN = lower limit of normal.
Note: obstruction GOLD = according to the GOLD defi nition: FEV1:FVC less than 0.70. Obstruction LLN = according to ERS: LLN of FEV1:FVC ratio for male patients: 
–0.18 x age + 87.21 – (1.64 x 7.17); for female patients: –0.19 x age + 89.10 – (1.64 x 6.51).
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